Related Experiment Video

Updated: Jun 28, 2026

Examination of Oral Candida Infection in Primary Sjögren's Syndrome Patients
05:26

Examination of Oral Candida Infection in Primary Sjögren's Syndrome Patients

Published on: March 1, 2024

Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome

Steven E Carsons1

  • 1SUNY at Stony Brook School of Medicine, Stony Brook, NY, USA. Scarsons@winthrop.org

Rheumatic Diseases Clinics of North America
|November 6, 2008
PubMed

Insights

Treatment for Sjögren

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Trials

Background:

  • Oral and biologic disease-modifying antirheumatic drugs (DMARDs) have yielded disappointing results in Sjögren's syndrome treatment.
  • Existing therapeutic options for Sjögren's syndrome are limited.

Purpose of the Study:

  • To review the challenges and potential future directions for developing effective disease-modifying treatments for Sjögren's syndrome.
  • To highlight the need for improved therapeutic strategies.

Main Methods:

  • Review of published studies and clinical trials on DMARDs for Sjögren's syndrome.
  • Discussion of advancements in clinical trial design and emerging therapeutic agents.

Main Results:

  • Past trials of oral and biologic DMARDs for Sjögren's syndrome have shown limited efficacy.
  • Improvements in trial design and the development of new agents offer future hope.

Conclusions:

  • Enhanced clinical trial design, including standardized measures and international collaboration, is crucial for Sjögren's syndrome research.
  • Emerging biologic, immunomodulatory, and small molecule agents hold promise for future Sjögren's syndrome therapies.

More Related Videos

Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights07:25

Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights

Published on: October 13, 2023

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...